This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Flmodafinil
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST HIGH
Cleaner pharmaceutical-grade armodafinil exists with FDA approval and 25+ years of safety data. Flmodafinil is the gray-market potency-upgrade route — only rational pick for users who literally cannot access pharmaceutical-grade modafinil/armodafinil. Verdict moves to SKIP if user has any pharmacy access; moves to consider only if (a) modafinil/armodafinil sourcing collapses AND (b) reliable third-party-tested vendor (Kimera Chems, Lordheim, Mountain Pure tier with COAs) remains operational AND (c) user accepts the unsurfaced-toxicity tail risk.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | WATCH-LIST | Modafinil 100 mg AM via Indian pharmacy is strictly dominant — established human PK/PD, 25+ years of safety data, cheap, reliable supply, known interactions. Armodafinil 150 mg AM via US telehealth is even cleaner. Flmodafinil offers no validated benefit over either pharmaceutical option and adds substantial unknown-unknowns to a 20yo brain that this user has explicitly named his most valuable asset. The "more potent / longer duration" pitch is not a benefit when modafinil already covers a full workday at 100 mg; the only real attraction is mg-for-mg potency, which is irrelevant when modafinil is cheap and abundant. Verdict only flips if pharmaceutical access disappears and the user has a reliable third-party-tested research-chem vendor. |
30-50, executive maintenance | WATCH-LIST | Same logic. Even cleaner Rx access via US telehealth. No reason to choose an uncharacterized compound. |
50+, mild cognitive decline | SKIP-FOR-NOW | Higher baseline cardiovascular and hepatic vulnerability + medication burden = an undocumented modafinil-class compound is a worse fit, not a better one. Use armodafinil with proper monitoring. |
Anxiety-prone | SKIP-FOR-NOW | The "calmer than modafinil" pitch is appealing but unsupported by human evidence. Higher effective DAT engagement could plausibly amplify anxiety, not reduce it. |
High athletic load, tested status | HARD SKIP | Likely WADA-banned by structural analogy to modafinil even though flmodafinil itself isn't explicitly listed (S6 catch-all language for "and other substances with similar chemical structure or biological effect"). Tested athletes have no use case. |
Sleep-disordered | SKIP-FOR-NOW | Modafinil/armodafinil/solriamfetol/pitolisant are FDA-approved with characterized safety profiles. Flmodafinil offers nothing useful. |
Recovery-focused (post-injury, post-illness) | SKIP-FOR-NOW | Adding undocumented compound load to a body in recovery is the wrong direction. |
Strength/anabolic-focused | NOT-RELEVANT | No anabolic effect; presumed modafinil-class appetite suppression interferes with bulking phases. |
No-pharmacy-access edge case (international, geographically restricted, etc.) | CONDITIONAL CONSIDER | If the user genuinely has no pharmaceutical path and wants a modafinil-class compound, flmodafinil with a reliable third-party-COA-publishing vendor is *arguably* the cleanest research-chem option in the eugeroic family — better than fladrafinil (no prodrug variability, lower hepatic load) and better than hydrafinil (substantially more characterized in patent literature). Still inferior to any pharmaceutical option. Universal verdict: Flmodafinil is dominated by armodafinil and modafinil for every user archetype with pharmaceutical access. It exists on the WATCH-LIST as the gray-market potency-upgrade route — relevant only when pharmaceutical paths are inaccessible. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)WATCH-LIST
Modafinil 100 mg AM via Indian pharmacy is strictly dominant — established human PK/PD, 25+ years of safety data, cheap, reliable supply, known interactions. Armodafinil 150 mg AM via US telehealth is even cleaner. Flmodafinil offers no validated benefit over either pharmaceutical option and adds substantial unknown-unknowns to a 20yo brain that this user has explicitly named his most valuable asset. The "more potent / longer duration" pitch is not a benefit when modafinil already covers a full workday at 100 mg; the only real attraction is mg-for-mg potency, which is irrelevant when modafinil is cheap and abundant. Verdict only flips if pharmaceutical access disappears and the user has a reliable third-party-tested research-chem vendor.
- 30-50, executive maintenanceWATCH-LIST
Same logic. Even cleaner Rx access via US telehealth. No reason to choose an uncharacterized compound.
- 50+, mild cognitive declineSKIP-FOR-NOW
Higher baseline cardiovascular and hepatic vulnerability + medication burden = an undocumented modafinil-class compound is a worse fit, not a better one. Use armodafinil with proper monitoring.
- Anxiety-proneSKIP-FOR-NOW
The "calmer than modafinil" pitch is appealing but unsupported by human evidence. Higher effective DAT engagement could plausibly amplify anxiety, not reduce it.
- High athletic load, tested statusHARD SKIP
Likely WADA-banned by structural analogy to modafinil even though flmodafinil itself isn't explicitly listed (S6 catch-all language for "and other substances with similar chemical structure or biological effect"). Tested athletes have no use case.
- Sleep-disorderedSKIP-FOR-NOW
Modafinil/armodafinil/solriamfetol/pitolisant are FDA-approved with characterized safety profiles. Flmodafinil offers nothing useful.
- Recovery-focused (post-injury, post-illness)SKIP-FOR-NOW
Adding undocumented compound load to a body in recovery is the wrong direction.
- Strength/anabolic-focusedNOT-RELEVANT
No anabolic effect; presumed modafinil-class appetite suppression interferes with bulking phases.
- No-pharmacy-access edge case (international, geographically restricted, etc.)CONDITIONAL CONSIDER
If the user genuinely has no pharmaceutical path and wants a modafinil-class compound, flmodafinil with a reliable third-party-COA-publishing vendor is *arguably* the cleanest research-chem option in the eugeroic family — better than fladrafinil (no prodrug variability, lower hepatic load) and better than hydrafinil (substantially more characterized in patent literature). Still inferior to any pharmaceutical option. Universal verdict: Flmodafinil is dominated by armodafinil and modafinil for every user archetype with pharmaceutical access. It exists on the WATCH-LIST as the gray-market potency-upgrade route — relevant only when pharmaceutical paths are inaccessible.
▸ Subjective experience (deep)
The honest answer: no clinical research has standardized this. What follows synthesizes forum reports with the explicit caveat that flmodafinil's actual human PK/PD has never been formally characterized.
Onset: Reportedly ~30-60 minutes orally, similar to or slightly faster than modafinil. The faster onset (vs. modafinil's typical 60-90 min) is consistent with improved BBB penetration but unverified.
Peak: ~2-4 hours.
Duration: 10-15+ hours subjectively reported. This is the most distinctive claimed feature — meaningfully longer than modafinil (12-15 hr terminal half-life but 6-8 hr useful subjective duration for most users) and marginally longer than armodafinil's smoother decline. The duration extension can become a sleep-disruption liability if dosed past mid-morning.
Characteristic effects (per user reports):
- Sustained wakefulness without modafinil's "edge" some users get
- Reduced motivation to socialize / chat (consistent with modafinil's task-focus profile)
- Mood neutralization — less affect, less reactivity
- Reduced appetite (presumed modafinil-class effect, possibly intensified by higher relative potency)
- Mild HR / BP elevation (presumed modafinil-class effect)
- Sleep disruption if dosed late — bigger concern than with modafinil due to extended duration
- Some users report a more "amphetamine-adjacent" feel at higher doses, consistent with stronger DAT engagement
Honest variability: High — possibly higher than modafinil's already-substantial variability, because there is no pharmaceutical-grade reference compound and vendor purity varies dramatically. Two users on "75 mg flmodafinil" may not be on the same compound, the same purity, or even the same dose actually delivered.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Presumed minimal (modafinil-class) but unverified for flmodafinil. The longer duration could plausibly accelerate tolerance compared to modafinil's daily clean-out window.
- Recommended cycle: Don't. If used despite the WATCH-LIST recommendation, mirror modafinil's 5-on, 2-off pattern with the additional caveat that the longer duration may make a 4-on, 3-off pattern preferable to allow full plasma washout.
- Reset protocol: N/A — no data. Modafinil's pitolisant-bridged tolerance reset (Cesta et al. 2023) has no replication data for flmodafinil.
▸ Stacking deep dive
Synergistic with (presumed modafinil-class)
- L-theanine 200 mg — same smoothing-the-edge logic as with modafinil. Likely the safest single co-administration.
- Caffeine (low dose) — modafinil-class additivity assumed, but flmodafinil's stronger DAT engagement makes the cardiovascular load potentially more relevant. 50-100 mg caffeine ceiling.
- Citicoline / Alpha-GPC — cholinergic substrate support for the cognitive load that modafinil-class drugs let you sustain.
- Bromantane — different mechanism, no overlap, plausibly synergistic (same logic as for modafinil/armodafinil). Also research-chem in this combination — additive unknown-unknowns.
Avoid stacking with
- Other modafinil-class eugeroics (modafinil, armodafinil, adrafinil, fladrafinil, hydrafinil, solriamfetol, pitolisant) — redundant DAT or wakefulness mechanism plus AUC stacking. Pick one.
- Classical stimulants (amphetamine, methylphenidate, focalin, lisdexamfetamine) — overstimulation, cardiovascular load, anxiety, sleep wreck. Possibly worse than with modafinil due to higher effective DAT engagement.
- MAO inhibitors (selegiline >10 mg, tranylcypromine, phenelzine) — hypertensive crisis risk. Hard contraindication.
- Hormonal contraceptives — assumed CYP3A4 induction (modafinil-class) reduces efficacy ~18%; same partner-relevant caveat.
- Yohimbine, high-dose synephrine — stacked alpha-1/alpha-2 effects = anxiety + BP spike.
- Other CYP3A4 inducers daily (rifampin, St. John's Wort, carbamazepine) — unpredictable plasma flmodafinil reduction.
Neutral / safe co-administration
- Cannot reliably define. Without a characterized drug-interaction profile, "neutral" is inference, not knowledge. Assume modafinil's documented interaction set as a starting point.
▸ Drug interactions deep dive
Presumed (by modafinil-class extrapolation):
- CYP3A4 induction → reduced hormonal contraceptive efficacy, reduced opioid analgesia, reduced levels of CYP3A4-substrate medications.
- Mild CYP2C19 inhibition → possibly elevated phenytoin, diazepam, omeprazole, esomeprazole levels.
- Modest hepatic load (lower than fladrafinil/adrafinil because flmodafinil is the active form, not a prodrug) — additive with other hepatotoxins still warrants caution.
Documented (in humans): None published.
▸ Pharmacogenomics
- CYP3A4 / CYP3A5 — presumed primary clearance pathway (modafinil-class).
- CYP2C19 — presumed secondary clearance pathway; poor metabolizers may experience extended duration / elevated AUC.
- HLA-B alleles — SJS-susceptibility pattern unknown for flmodafinil specifically; HLA-B15:02 and HLA-B57:01 SJS associations exist for other compounds in this class but flmodafinil-specific data is absent.
- For the user: Awaiting 23andMe results in June 2026. Even with full pharmacogenomic data, there is no rational reason to apply it to a compound with no human PK/PD baseline. Use armodafinil or modafinil and benefit from genuine PGx-modafinil data.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research-chem vendor | Kimera Chems, Lordheim, Mountain Pure (rotating) | $40-90 / 30 caps (50-100 mg each, dosing variable) | Low | The "tier-1" research-chem vendors do third-party COAs (variable quality). Vendor names rotate as enforcement actions and supply chains shift. As of 2026, supply is intermittent. |
| Bulk powder | International research-chem | $80-200 / gram | Low | Even less consistent than capsules. Requires precise milligram scale. Often the only path when capsule vendors are between batches. |
| Indian pharmacy | None | N/A | N/A | No pharmaceutical-grade source exists in any jurisdiction — never approved. |
| Rx anywhere | None | N/A | N/A | Cephalon abandoned development; no commercial pharmaceutical filing exists. |
Bottom line on sourcing: Flmodafinil is research-chem-only in 2026 with rotating, intermittent vendor supply. Vendor reliability is the central practical issue — even the better vendors (those publishing third-party COAs) carry batch-to-batch variability that pharmaceutical-grade modafinil/armodafinil simply does not. Indian-pharmacy modafinil sourcing (ModafinilXL or similar, $0.50-1.50/pill, WHO-GMP Sun Pharma source) is dramatically cleaner; US telehealth Rx for armodafinil is even cleaner. The only legitimate use case for flmodafinil sourcing is if both pharmacy paths are inaccessible.
▸ Biomarkers to track (deep)
If used despite the WATCH-LIST recommendation, mirror the modafinil monitoring protocol with extended skin-rash and cardiovascular watch periods given the absence of formal surveillance:
Baseline (before starting)
- ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin (full LFT panel)
- Resting HR + BP (3-day morning average)
- Skin photographic baseline (week 1-8 SJS-class watch — extended given no surveillance for flmodafinil)
- Anxiety baseline (GAD-7 or daily VAS)
- Sleep onset latency baseline (smartphone or wearable; extended-duration concern)
During use
- Week 4: full LFT panel + BP/HR check — stop drug if ALT or AST >3× ULN, or any clinical symptoms (RUQ pain, jaundice, dark urine, persistent fatigue), or BP elevation >10 mmHg sustained.
- Week 12: full LFT panel — same threshold.
- Quarterly thereafter: full LFT panel + BP/HR.
- Weeks 1-12: daily skin check (extended past modafinil's 8-week window because no surveillance data exists for flmodafinil specifically).
- Weekly: sleep onset latency tracking — flmodafinil's longer duration creates higher cumulative sleep-disruption risk than modafinil.
Post-cycle
- LFT recheck 6-8 weeks after discontinuation if any week-4 or week-12 elevation seen.
▸ Controversies / open debates Live debate
1. "Flmodafinil is 3-4× more potent than modafinil mg-for-mg"
- Forum claim: Subjective reports converge on this characterization.
- Reality: Plausible chemistry (lipophilicity-driven BBB penetration) and consistent forum reports across years and venues, but no clinical PK study has measured plasma concentration vs. modafinil-equivalent dose. The 3-4× number is forum-aggregated subjective dose-finding, not measurement. Could be 2× or could be 5× depending on individual variability.
2. "Flmodafinil is the cleaner long-duration option"
- Vendor / forum claim: Yes — citing 10-15 hr subjective duration.
- Reality: Possibly true subjectively. Whether the longer duration is clean (smooth decline, no rebound) or just long (extended plateau followed by abrupt offset) varies by report. Armodafinil's already-characterized 15-hour profile makes flmodafinil's putative duration advantage marginal at best.
3. "Cephalon abandoned flmodafinil because it was too potent / too good"
- Counter-narrative in some nootropic circles: Big-pharma suppression / Cephalon protected modafinil franchise by killing flmodafinil.
- Actual record: Cephalon developed modafinil → armodafinil specifically because the R-enantiomer route was a faster, cheaper regulatory path than novel-chemical-entity flmodafinil. Armodafinil leveraged modafinil's existing efficacy and safety database; flmodafinil would have required a full new-NCE filing. The decision was developability and regulatory economics, not suppression of a "too good" compound.
4. "Flmodafinil bypasses the prodrug overhead of fladrafinil/adrafinil"
- Forum claim: Yes.
- Reality: This one is true. Flmodafinil is the active sulfinyl form directly, structurally analogous to modafinil rather than to the N-hydroxyacetamide prodrug skeleton. It does not depend on hepatic conversion the way adrafinil and fladrafinil do, which means lower interindividual variability and lower hepatic load. This is the strongest pharmacological argument for flmodafinil over fladrafinil within the research-chem cohort.
5. "Lauflumide is a different compound from flmodafinil"
- Confusion in nomenclature: Forum users sometimes treat "lauflumide" and "flmodafinil" as separate compounds, or one as the prodrug of the other.
- Reality: Lauflumide and flmodafinil refer to the same compound (CRL-40,940 / bisfluoromodafinil) under different naming conventions. The nomenclature is not standardized in research-chem channels and vendors use either name interchangeably. There is no established second compound with a meaningfully different structure.
6. "Research-chem availability makes flmodafinil the only legal option"
- Historical edge case: True for some users in regions with no Indian-pharmacy access or US telehealth path.
- Current reality (2026): ModafinilXL and similar Indian-pharmacy vendors ship internationally to most jurisdictions. US telehealth Rx for armodafinil/modafinil is straightforward for adults with documented sleep complaints. The legal-access argument applies to a much smaller user population than research-chem-vendor marketing implies.
▸ Verdict change log
- 2026-05-10 — Initial verdict: WATCH-LIST / HIGH CONFIDENCE / MEDIUM-priority research pass. WATCH-LIST rather than SKIP-FOR-NOW because (a) flmodafinil has the cleanest pharmacology profile within the eugeroic research-chem cohort (active form, not prodrug, no adrafinil-class hepatic toll), (b) Cephalon-era patent literature provides more formal preclinical context than fladrafinil has, (c) the gray-market potency-upgrade use case is real for a subset of users without pharmaceutical access. WATCH-LIST tracks the compound for cases where pharmaceutical sourcing constraints actually bind. For users in this archetype with established Indian-pharmacy modafinil access, verdict is functionally SKIP — armodafinil or modafinil strictly dominate.
▸ Open questions / gaps Open
- Zero published human PK data. No phase-1, no DAT-occupancy PET, no plasma-concentration vs. dose curves, no half-life confirmation. The 12+ hour estimated half-life is structural inference plus subjective duration reports, not measurement.
- No published human safety surveillance. Hepatic, dermatologic, and cardiovascular profiles all unknown for flmodafinil specifically.
- No comparator trial against modafinil or armodafinil. The "3-4× more potent / 10-15 hr duration" claims are unfalsifiable without head-to-head data.
- Cephalon-era preclinical data is incomplete in public literature. Most CRL-40,940 references are patent filings rather than peer-reviewed papers; the actual animal pharmacology data sits in industry archives.
- Vendor reliability fluctuates. Kimera Chems / Lordheim / Mountain Pure tier vendors come and go; quality control varies batch-to-batch. The "reliable third-party-COA-publishing vendor" condition that pushes flmodafinil from WATCH-LIST to CONDITIONAL CONSIDER is itself unstable.
- WADA classification ambiguous. Likely banned by S6 catch-all language but never explicitly listed.
- What would change the verdict toward CONSIDER? A published phase-1 PK/PD study + comparator efficacy data against modafinil + a stable pharmaceutical-grade source. None of these are realistically in motion in 2026-2027.
- What would change the verdict toward SKIP-PERMANENT? An emergent safety signal in case-report literature (hepatic, dermatologic, cardiovascular) that distinguishes flmodafinil from modafinil-class baseline, or further consolidation of pharmaceutical-grade modafinil/armodafinil access globally.
References
Battleday & Brem 2015 — Modafinil for cognitive neuroenhancement systematic review (PMID 26381811)
the modafinil A-tier evidence baseline that flmodafinil completely lacks.
View StudyDarwish et al. 2009 — Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles (PMID 19663523)
the kind of formal PK study that exists for armodafinil and does not exist for flmodafinil.
View StudyModafinil — Wikipedia 2026
primary structural and historical reference for the parent compound; CRL-series development context.
View SourceLafon Laboratoires — CRL-series program history
context for the Lafon → Cephalon → Teva development chain that produced modafinil, armodafinil, and the abandoned analogs (CRL-40,940 flmodafinil, CRL-40,941 fladrafinil, CRL-40,028 adrafinil).
View SourceModafinil compound file
gold-standard eugeroic comparator; pharmaceutical-grade alternative.
View SourceArmodafinil compound file
closest pharmaceutical analog by mechanism + duration; the route Cephalon chose over flmodafinil.
View SourceFladrafinil compound file
sibling research-chem compound (bisfluoro adrafinil prodrug); useful contrast for prodrug vs. active-form pharmacology.
View SourceAdrafinil compound file
prodrug parent of fladrafinil; useful for hepatic-load contrast (flmodafinil does not inherit this).
View SourceModafinil/Armodafinil — LiverTox NCBI Bookshelf NBK548274
modafinil hepatic safety baseline (likelihood E); flmodafinil's expected baseline by class.
View SourceWADA Prohibited List 2026
modafinil banned S6 in-competition; flmodafinil likely covered by S6 catch-all language.
View SourceNootropics Encyclopedia 2026-05-05
internal reference; broader CRL-series and modafinil-family context.
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.